These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. Majumdar SR, McAlister FA, Cree M, Chang WC, Packer M, Armstrong PW, ATLAS Study Group. Clin Ther; 2004 May; 26(5):694-703. PubMed ID: 15220013 [Abstract] [Full Text] [Related]
4. Management of heart failure among very old persons living in long-term care: has the voice of trials spread? The SAGE Study Group. Gambassi G, Forman DE, Lapane KL, Mor V, Sgadari A, Lipsitz LA, Bernabei R. Am Heart J; 2000 Jan; 139(1 Pt 1):85-93. PubMed ID: 10618567 [Abstract] [Full Text] [Related]
10. Review of randomized trials of digoxin therapy in patients with chronic heart failure. Gheorghiade M, Zarowitz BJ. Am J Cardiol; 1992 Jun 04; 69(18):48G-62G; discussion 62G-63G. PubMed ID: 1626492 [Abstract] [Full Text] [Related]
12. Comparison of one-year outcome (death and rehospitalization) in hospitalized heart failure patients with left ventricular ejection fraction >50% versus those with ejection fraction <50%. Ezekowitz JA, Lee DS, Tu JV, Newman AM, McAlister FA. Am J Cardiol; 2008 Jul 01; 102(1):79-83. PubMed ID: 18572040 [Abstract] [Full Text] [Related]
13. The effect of digoxin on mortality and morbidity in patients with heart failure. Digitalis Investigation GroupMount Sinai Medical Center, New York, NY 10029-6574, USA.. N Engl J Med; 1997 Feb 20; 336(8):525-33. PubMed ID: 9036306 [Abstract] [Full Text] [Related]
18. Angiotensin converting enzyme inhibitors versus digoxin for the treatment of congestive heart failure. Crozier I, Ikram H. Drugs; 1992 May 20; 43(5):637-50. PubMed ID: 1379144 [Abstract] [Full Text] [Related]
19. Pharmacoeconomic considerations in assessing and selecting congestive heart failure therapies. Levy E, Levy P. Pharmacoeconomics; 2002 May 20; 20(14):963-77. PubMed ID: 12403637 [Abstract] [Full Text] [Related]
20. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET). Massie BM, Berk MR, Brozena SC, Elkayam U, Plehn JF, Kukin ML, Packer M, Murphy BE, Neuberg GW, Steingart RM. Circulation; 1993 Aug 20; 88(2):492-501. PubMed ID: 8339411 [Abstract] [Full Text] [Related] Page: [Next] [New Search]